SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is highly volatile amid escalating Middle East tensions, with initial surges driven by Strait of Hormuz disruption fears and production cuts now battling signals of de-escalation from presidential remarks and G7 discussions on strategic oil reserve releases. This has led to a polarized community debate on its immediate trajectory.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending after reporting robust Q4 earnings that significantly surpassed expectations, driven by strong sales of its rare disease drug MIPLYFFA and marking the company's achievement of profitability. This financial performance is fueling widespread community excitement, with many speculating on a potential short squeeze and re-evaluating the stock's value as a commercially successful rare disease player.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is drawing significant attention after being selected for a White House-backed eVTOL integration program to accelerate U.S. operations, alongside the launch of Uber Air in Dubai for commercial service. The community is actively debating these tangible commercialization milestones and progress towards FAA certification, even as new allegations from a competitor's lawsuit and a short report fuel further discussion.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense & National Security, Space Solutions, and Starlab Space Stations. The Defense & National Security segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Space Solutions segment consists of space infrastructure, advanced space technology, science systems and mission services. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyager Technologies Inc

Voyager Technologies is trending following its recent Q4 earnings, which reported record net sales and a substantial backlog driven by its defense segment, alongside a positive 2026 outlook. The community is actively engaged in discussions around this strong performance and the transformative potential of its Starlab commercial space station as it anticipates crucial NASA contract developments.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

Casey's General Stores is trending as its recent earnings reports, which often highlighted strong EPS performance and consistent inside sales, spark debate about its valuation amid occasional revenue misses and slowing same-store growth in key categories. The community actively discusses its unique model, notable pizza sales, and ongoing expansion within the convenience store sector.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is drawing significant attention following its recent U.S. Department of Energy agreement for Project TEFLA, a crucial step in integral molten salt reactor fuel production, which the community sees as a catalyst for its long-term potential in powering AI data centers and positions it as an undervalued player in the advanced nuclear sector.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is trending following strong Q1 earnings that beat EPS estimates and demonstrated significant growth in its networking segment, fueled by robust AI demand and the strategic integration of Juniper Networks. The community is actively discussing HPE's positioning as an undervalued full-stack AI infrastructure player, poised to challenge competitors in both server and networking solutions.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is experiencing a massive price and volume surge as a short squeeze narrative takes hold, fueled by discussions around its recent private placement financing and updates to its lead candidate's Phase 3 trial status. Community sentiment is polarized between expectations of significant further gains and warnings of a pump-and-dump, reflecting the stock's historical volatility.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil (SCO) is trending as traders debate its tracking performance amidst extreme volatility in crude oil prices driven by geopolitical tensions. Many in the community are anticipating a significant pullback in oil from perceived overbought levels, viewing SCO as an opportunity to capitalize on an eventual decline.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is trending as investors eye a significant rebound in Chinese internet stocks, fueled by expectations of progress in US-China trade relations and China's strategic pivot towards high-tech industries and domestic stimulus. Community sentiment highlights deeply oversold technicals and compelling valuations, with notable options flow indicating strong bullish conviction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Recommendation of "Moderate Buy" from Brokerages

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the thirteen research firms that are currently covering the firm...

Oppenheimer Has Lowered Expectations for Aardvark Therapeutics (NASDAQ:AARD) Stock Price

Oppenheimer cut their price target on Aardvark Therapeutics from $35.00 to $21.00 and set an "outperform" rating for the company in a report on Monday...

<ul class="summary-bullets"><li>Aardvark voluntarily paused the HERO Phase 3 trial on Friday after a routine safety monitoring of a healthy volunteer found reversible cardiac effects.</li><li>Aardvark said it no longer expects to release HERO trial topline data in Q3 2026.</li><li>Stifel called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.”</li></ul>Shares of Aardvark Therapeutics (AARD) plummeted 4% in pre-market trading on Monday after a wave of bearish analyst downgrades following the company’s decision to pause its Phase 3 trial evaluating the treatment for hyperphagia in patients with Prader-Willi syndrome.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/AARD">AARD shares</a> could fall to their lowest levels since Apr. 9, 2025.On Friday, Aardvark said it voluntarily paused the HERO Phase 3 and related extension trials after a routine safety monitoring of a healthy volunteer found reversible cardiac effects at doses above the target therapeutic level.Aardvark said it no longer expects to release HERO trial topline data in the third quarter (Q3) of 2026 and will instead provide updated guidance in the second quarter.<h2 class="st-heading-2">Analyst Expresses Skepticism About The New Uncertainty</h2>Stifel downgraded Aardvark Therapeutics to ‘Hold’ from ‘Buy’ and reduced its price target to $6 from $24, according to The Fly. This represents a 52% downside to Friday’s closing price of $12.5. The brokerage called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.” It is “very hard to build confidence in what the path forward may look like,” Stifel added.Morgan Stanley downgraded Aardvark Therapeutics to ‘Equal Weight’ from ‘Overweight’ and significantly slashed its price target to $7 from $29, according to The Fly. While the brokerage still sees potential for ARD-101, it lowered its rating due to near-term uncertainties.RBC Capital said that timelines are likely to be significantly delayed as the Aardvark works with the FDA on next steps, adding a “layer of uncertainty” around the program. The brokerage downgraded the stock to ‘Sector Perform’ from ‘Outperform’ and cut its price target to $6 from $18.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>While retail sentiment on Stocktwits remained ‘extremely bullish,’ amid ‘extremely high’ message volumes, chatter was largely ‘bearish’.<img src="https://news.stocktwits-cdn.com/AARD_jpg_eaa4fec962.webp" alt="AARD.jpg">One user said the suspension of the trial was “one of the worst news.”<stembedurl>https://stocktwits.com/focafoca99/message/646219667</stembedurl>Another user expects the stock to decline to $3.<stembedurl>https://stocktwits.com/jojoraizza/message/646210388</stembedurl>The stock has lost around 56% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spy-falls-100-day-moving-average-oil-vix-middle-east-tensions/cZd33g2RIcH">SPY On Track To Fall Below 100-DMA For First Time In Nine Months – Retail Braces For Prolonged Volatility</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

Equity

Aardvark Therapeutics (NASDAQ:AARD) Given New $9.00 Price Target at BTIG Research

BTIG Research reduced their price objective on shares of Aardvark Therapeutics from $26.00 to $9.00 and set a "buy" rating on the stock in a research note on Monday...

Aardvark Therapeutics (NASDAQ:AARD) Earns "Equal Weight" Rating from Morgan Stanley

Morgan Stanley restated an "equal weight" rating and issued a $7.00 target price (down from $29.00) on shares of Aardvark Therapeutics in a research report on Monday...

HC Wainwright Reaffirms Neutral Rating for Aardvark Therapeutics (NASDAQ:AARD)

HC Wainwright restated a "neutral" rating on shares of Aardvark Therapeutics in a research report on Monday...

Aardvark Therapeutics' (AARD) "Hold" Rating Reiterated at Stifel Nicolaus

Stifel Nicolaus reaffirmed a "hold" rating and set a $6.00 price target (down from $24.00) on shares of Aardvark Therapeutics in a research note on Monday...

AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (Aardvark or the Company) (NASDAQ...

<ul class="summary-bullets"><li>Aardvark was studying the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome in the trial.</li><li>In September, Acadia Pharmaceuticals scrapped development of intranasal Carbetocin after it failed to meet the key goals in a late-stage PWS trial.</li><li>Soleno Therapeutics’ VYKAT XR is the first approved treatment specifically for hyperphagia in PWS patients.</li></ul>Shares of Aardvark Therapeutics (AARD) dived 53% after hours on Friday after the company announced that it is voluntarily pausing its late-stage trial in Prader-Willi Syndrome (PWS).The company was studying the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome in the trial. Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, estimated to occur in one in every 15,000 live births. The disorder is defined by hyperphagia, an intense, persistent sensation of hunger, which could be life-threatening.<h2 class="st-heading-2">Why Is Aardvark Pausing Trial?</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aardvarktherapeutics.com/news-releases/news-release-details/aardvark-therapeutics-announces-voluntary-pause-phase-3-hero">said</a> that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study. The company is reviewing the data to determine next steps, it said, while adding that it has also paused enrollment and dosing in the trial as it completes its evaluation.The firm also added that it no longer expects data from the trail in the third quarter of 2026.<h2 class="st-heading-2">Other Names To Quit PWS Drug Development</h2>In September, Acadia Pharmaceuticals <a href="https://stocktwits.com/news-articles/markets/equity/acadia-pharmaceuticals-investigational-drug-for-rare-genetic-disorder-fails-in-late-stage-study/chD1Gf0R33B">scrapped</a> development of intranasal Carbetocin after it failed to meet the key goals in a late-stage PWS trial.The company then said that intranasal Carbetocin did not demonstrate a statistically significant improvement over placebo to week 12 on the Hyperphagia Questionnaire for Clinical Trials and also announced its intent to stop investigating the drug further.<h2 class="st-heading-2">Soleno’s Approved Drug</h2>Soleno Therapeutics, meanwhile, received FDA approval of VYKAT XR in early 2025, making it the first approved treatment specifically for hyperphagia in PWS patients.However, in August, Scorpion Capital revealed a short position against Soleno stock, alleging several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure. Scorpion Capital also stated that it intends to submit an emergency Citizen Petition shortly, requesting that the FDA urge Soleno to conduct a voluntary recall of Vykat XR from the market.Weeks later, in September, the company <a href="https://stocktwits.com/news-articles/markets/equity/soleno-therapeutics-stock-tanks-after-patient-treated-with-drug-dies/chwklo0RdHG">stated</a> in a filing with the Securities and Exchange Commission that it is aware of a serious adverse event reported in the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) involving a deceased patient. However, the existence of a report in the data does not establish causation, the company said.Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AARD rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/AARD">AARD stock</a> has dropped 7% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sls-stokes-retail-anticipation-for-breakout-rally/cZTcDCwRITx">SLS Stokes Retail Anticipation For Breakout Rally — What’s Driving The Interest?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts 

The company said that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study.

Aardvark Therapeutics Establishes Ardia Subsidiary To Advance Dermatology Pipeline

(RTTNews) - Aardvark Therapeutics Inc. (AARD) announced on Thursday the formation of Ardia Therapeutics Inc., a wholly owned U.S. subsidiary focused on building a dermatology pipeline...

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.83	--	--	N/A
Q3 '25	-$0.80	-$0.75	6.08%	BEAT
Q2 '25	-$0.60	-$0.66	-10.00%	MISSED
Q1 '25	-$0.67	-$0.71	-5.45%	MISSED

AARD
Aardvark Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest AARD News

AARDAardvark Therapeutics Inc